Daniel Salerno, MD
Pulmonary Disease · Philadelphia, PANPI 1902027535
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Insmed, Inc.. That places this record below the midpoint for pulmonary disease clinicians in PA, where the typical reported total is $988.
Across 2 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$34
Across 50 payments — averaging $2882.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Verona Pharma, Inc.$55K
- Regeneron$48K
- Mannkind Corporation$42K
What the payments were for
- Food & beverage$34100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 2 | $34 |
How this compares
$34 in reported general payments places this provider in the 10th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $178,075 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $92,210 |
| Dupixent SyringeDupilumab | 24 | $87,630 |
| NucalaMepolizumab | 24 | $82,443 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 54 | $36,068 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $34,112 |
| Pirfenidone | 18 | $31,496 |
| Spiriva RespimatTiotropium Bromide | 45 | $26,093 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $18,834 |
| Incruse ElliptaUmeclidinium Bromide | 53 | $18,227 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $15,158 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 199 | $6,617 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,808 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $5,202 |
| Varenicline Tartrate | 22 | $4,049 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.